PAK4 siRNA (h) from Santa Cruz Biotechnology, Inc.

Product Specs
ItemPAK4 siRNA (h)
CompanySanta Cruz Biotechnology, Inc.
Price $293.00Supplier Page View Company Product Page
Catalog Numbersc-39060
Gene Namep21 protein (Cdc42/Rac)-activated kinase 4
Quantity10 µM
Specieshuman
NCBI Full Gene Namep21 (RAC1) activated kinase 4
TypesiRNA/dsRNA

Add to Compare List

Santa Cruz Biotechnology, Inc.

10410 Finnell Street

Dallas, Texas 75220

United States

Phone: 1-800-457-3801
831-457-3801

Company Profile

Website: http://www.scbt.com/

(1) PAK4 Is Involved in the Stabilization of PD-L1 and the Resistance to Doxorubicin in Osteosarcoma and Predicts the Survival of Diagnosed PatientsCellsAugust 28, 2024Junyue Zhang, Yiping Song, Ae-Ri Ahn, Ho Sung Park, See-Hyoung Park, Young Jae Moon, Kyoung Min Kim, Kyu Yun Jangand 1% penicillin/streptomycin. The vector for PAK4-specific shRNA was purchased from Santa Cruz (#SC-39060, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The overexpression of PAK4 was induced via the transfection

(2) Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferationSmall GTPasesSeptember 1, 2019Mohammad RM, Li Y, Muqbil I, Aboukameel A, Senapedis W, Baloglu E, Landesman Y, Philip PA, Azmi AS.

(3) MiR-199a-3p decreases esophageal cancer cell proliferation by targeting p21 activated kinase 4OncotargetJune 19, 2018Phatak P, Burrows WM, Chesnick IE, Tulapurkar ME, Rao JN, Turner DJ, Hamburger AW, Wang JY, Donahue JM.utilized. For RNA silencing, 80 pmol of either PAK4-siRNA-1[Santa Cruz Biotechnologies (catalog no sc39060)] or PAK4-siRNA-2 [Dharmacon Inc (catalog no L003615-00)] were used. Each of these siRNAs contain pools

(4) MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathwayBMC cancerJanuary 5, 2018Zeng B, Shi W, Tan G.

(5) A novel interaction of PAK4 with PPARγ to regulate Nox1 and radiation-induced epithelial-to-mesenchymal transition in gliomaOncogeneSeptember 14, 2017Kesanakurti D, Maddirela D, Banasavadi-Siddegowda YK, Lai TH, Qamri Z, Jacob NK, Sampath D, Mohanam S, Kaur B, Puduvalli VK.

(6) Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal AdenocarcinomaMolecular cancer therapeuticsJanuary 1, 2017Aboukameel A, Muqbil I, Senapedis W, Baloglu E, Landesman Y, Shacham S, Kauffman M, Philip PA, Mohammad RM, Azmi AS.

(7) PAK4 confers the malignance of cervical cancers and contributes to the cisplatin-resistance in cervical cancer cells via PI3K/AKT pathwayDiagnostic pathologySeptember 28, 2015Shu XR, Wu J, Sun H, Chi LQ, Wang JH.

(8) MicroRNA-433 inhibits cell proliferation in hepatocellular carcinoma by targeting p21 activated kinase (PAK4)Molecular and cellular biochemistryJanuary 1, 2015Xue J, Chen LZ, Li ZZ, Hu YY, Yan SP, Liu LY.

(9) PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathwaysBioscience reportsApril 1, 2014Fu X, Feng J, Zeng D, Ding Y, Yu C, Yang B.RNA interference (siRNA) was used to down-regulate PAK4 expression in AGS/CDDP and MKN-45/CDDP cells. PAK4 siRNA (sc-39060, Cell Santa Cruz Biotechnology) that specifically inhibits the expression of PAK4 was used. siRNA (50

(10) Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinomaCancer scienceOctober 1, 2009Begum A, Imoto I, Kozaki K, Tsuda H, Suzuki E, Amagasa T, Inazawa J.

Be the First to Write a Review!

PAK4 siRNA (h)

PAK4 siRNA (h) from Santa Cruz Biotechnology, Inc.

Description

Santa Cruz Biotechnology, Inc.

Citations (10)

Reviews

PAK4 siRNA (h) from Santa Cruz Biotechnology, Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map